Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05065567 · ClinicalTrials.gov registry record · Phase 3
Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis
A Phase 3 study, sponsored by Corewell Health South.
- Terminated
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
NCT05065567: Clinical Trial Phase 3 study, sponsored by Corewell Health South.
NCT05065567 is a Phase 3 study that was terminated before completion, run by Corewell Health South. The registered enrollment target is 32 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05065567, a Phase 3 study, was terminated before completion, sponsored by Corewell Health South.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to compare two commonly used agents for the treatment of cyclic vomiting to see if one agent is inferior to the other in time to improvement in symptoms, need for repeat or rescue medications, treatment failures and complications/side effects.
Primary Outcome
change in abdominal pain on 0 (no pain) through 10 (worse possible pain) on a visual analog scale
Interventions
- DRUG Haloperidol
- DRUG Ondansetron 8mg
- DRUG Droperidol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-08-30 |
| Est. Completion | 2023-11-20 |
| Phase | Phase 3 |
Why NCT05065567 stopped before completion
NCT05065567 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Haloperidol is the first listed.
NCT05065567 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05065567 about?
NCT05065567 is a clinical study titled "Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis". The purpose of this study is to compare two commonly used agents for the treatment of cyclic vomiting to see if one agent is inferior to the other in time to improvement in symptoms, need for repeat or rescue medications, treatment failures and complications/side effects.
What is the current status of trial NCT05065567?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2021-08-30. Estimated completion is 2023-11-20.
What interventions are being tested in trial NCT05065567?
The interventions under investigation include: Haloperidol (DRUG), Ondansetron 8mg (DRUG), Droperidol (DRUG).
Who is sponsoring clinical trial NCT05065567?
This trial is sponsored by Corewell Health South, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05065567's enrollment target sits among peer trials
32 1909th of 2000 higher than 87 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI